Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS: In this post hoc anal...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Eur Heart J
मुख्य लेखकों: Docherty, Kieran F, Jhund, Pardeep S, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, DeMets, David L, Sabatine, Marc S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Desai, Akshay S, Diez, Mirta, Howlett, Jonathan G, Katova, Tzvetana, Ljungman, Charlotta E A, O’Meara, Eileen, Petrie, Mark C, Schou, Morten, Verma, Subodh, Vinh, Pham Nguyen, Solomon, Scott D, McMurray, John J V
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2020
विषय:
Fast Track Clinical Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327533/
https://ncbi.nlm.nih.gov/pubmed/32221582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa183
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन